S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.59 (+1.03%)
AAPL   173.06 (+0.38%)
MSFT   317.95 (+1.46%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.70 (+1.59%)
TSLA   258.17 (+4.72%)
NVDA   438.87 (+0.85%)
NIO   8.76 (+1.74%)
BABA   84.07 (-0.56%)
AMD   102.47 (+2.39%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.47%)
GE   108.45 (+0.64%)
DIS   79.29 (-0.31%)
AMC   8.02 (+2.17%)
PFE   33.28 (-1.83%)
PYPL   58.12 (+1.43%)
NFLX   375.94 (-0.21%)
S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.59 (+1.03%)
AAPL   173.06 (+0.38%)
MSFT   317.95 (+1.46%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.70 (+1.59%)
TSLA   258.17 (+4.72%)
NVDA   438.87 (+0.85%)
NIO   8.76 (+1.74%)
BABA   84.07 (-0.56%)
AMD   102.47 (+2.39%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.47%)
GE   108.45 (+0.64%)
DIS   79.29 (-0.31%)
AMC   8.02 (+2.17%)
PFE   33.28 (-1.83%)
PYPL   58.12 (+1.43%)
NFLX   375.94 (-0.21%)
S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.59 (+1.03%)
AAPL   173.06 (+0.38%)
MSFT   317.95 (+1.46%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.70 (+1.59%)
TSLA   258.17 (+4.72%)
NVDA   438.87 (+0.85%)
NIO   8.76 (+1.74%)
BABA   84.07 (-0.56%)
AMD   102.47 (+2.39%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.47%)
GE   108.45 (+0.64%)
DIS   79.29 (-0.31%)
AMC   8.02 (+2.17%)
PFE   33.28 (-1.83%)
PYPL   58.12 (+1.43%)
NFLX   375.94 (-0.21%)
S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.59 (+1.03%)
AAPL   173.06 (+0.38%)
MSFT   317.95 (+1.46%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.70 (+1.59%)
TSLA   258.17 (+4.72%)
NVDA   438.87 (+0.85%)
NIO   8.76 (+1.74%)
BABA   84.07 (-0.56%)
AMD   102.47 (+2.39%)
T   14.57 (-1.42%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.47%)
GE   108.45 (+0.64%)
DIS   79.29 (-0.31%)
AMC   8.02 (+2.17%)
PFE   33.28 (-1.83%)
PYPL   58.12 (+1.43%)
NFLX   375.94 (-0.21%)
NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) News Today

Compare
Today's Range
N/A
50-Day Range
$1.26
▼
$1.59
52-Week Range
N/A
Volume
23,000 shs
Average Volume
127,289 shs
Market Capitalization
$2.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media
SourceHeadline
finance.yahoo.com logoScinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
finance.yahoo.com - October 4 at 8:27 AM
MarketBeat logoBiondVax Pharmaceuticals (NASDAQ:BVXV) Earns Hold Rating from Analysts at StockNews.com
americanbankingnews.com - October 2 at 3:18 AM
MarketBeat logoBiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - September 24 at 3:25 AM
finance.yahoo.com logoScinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
finance.yahoo.com - September 19 at 7:16 PM
finance.yahoo.com logoScinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
finance.yahoo.com - September 15 at 9:38 AM
finance.yahoo.com logoScinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
finance.yahoo.com - September 13 at 5:42 PM
finance.yahoo.com logoScinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
finance.yahoo.com - September 11 at 9:40 AM
financialpost.com logoBiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
financialpost.com - September 6 at 6:02 AM
finanznachrichten.de logoBiondVax Pharmaceuticals Ltd.: BiondVax Reports Second Quarter Financial Results and Provides Business Update
finanznachrichten.de - August 11 at 7:21 PM
finance.yahoo.com logoBiondVax Reports Second Quarter Financial Results and Provides Business Update
finance.yahoo.com - August 11 at 7:21 PM
finanznachrichten.de logoBiondVax Pharmaceuticals Ltd.: Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
finanznachrichten.de - August 2 at 9:46 AM
finance.yahoo.com logoNasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
finance.yahoo.com - August 1 at 6:44 PM
theglobeandmail.com logoBiondVax (NASDAQ: BVXV) Leveraging NanoAb Pipeline to Target Large Markets
theglobeandmail.com - July 28 at 10:11 PM
finance.yahoo.com logoIBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
finance.yahoo.com - July 11 at 12:04 PM
finance.yahoo.com logoBVXV - BiondVax Pharmaceuticals Ltd.
finance.yahoo.com - July 6 at 7:55 AM
finance.yahoo.com logoBiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
finance.yahoo.com - June 5 at 7:48 AM
finance.yahoo.com logoBVXV: Developing anti-IL-17 NanoAb
finance.yahoo.com - May 30 at 3:37 PM
finanznachrichten.de logoBiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
finanznachrichten.de - May 15 at 7:27 PM
msn.com logoBiondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73
msn.com - May 15 at 7:27 PM
finance.yahoo.com logoBiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 7:27 PM
theglobeandmail.com logoBiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team
theglobeandmail.com - April 20 at 6:40 PM
finanznachrichten.de logoBiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
finanznachrichten.de - April 18 at 7:31 AM
marketwatch.com logoBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
marketwatch.com - April 4 at 10:52 AM
marketwatch.com logoBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
marketwatch.com - March 26 at 8:33 PM
finance.yahoo.com logoBiondVax to Present at BIO-Europe Spring
finance.yahoo.com - March 16 at 2:18 PM
finance.yahoo.com logoIBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
finance.yahoo.com - March 6 at 6:39 PM
finance.yahoo.com logoIBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
finance.yahoo.com - March 3 at 4:30 PM
finance.yahoo.com logoBiondVax Presenting at BIO CEO & Investor Conference
finance.yahoo.com - February 2 at 3:09 PM
benzinga.com logoBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
benzinga.com - January 25 at 2:43 PM
benzinga.com logoBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19
benzinga.com - January 25 at 2:43 PM
markets.businessinsider.com logoBiondVax Pharma: In Vivo Data Shows NanoAb Virtually Prevents COVID-19 In Hamsters
markets.businessinsider.com - January 23 at 3:20 PM
finance.yahoo.com logoBiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate
finance.yahoo.com - January 23 at 3:20 PM
it.tmcnet.com logoBiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
it.tmcnet.com - January 23 at 8:38 AM
finance.yahoo.com logoBiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
finance.yahoo.com - January 23 at 8:38 AM
benzinga.com logoBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs
benzinga.com - January 15 at 2:57 PM
marketbeat.com logo
marketbeat.com - January 6 at 9:50 AM
benzinga.com logoBiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
benzinga.com - January 6 at 8:15 AM
finance.yahoo.com logoBiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
finance.yahoo.com - January 6 at 8:14 AM
finance.yahoo.com logoBiondVax to Present at Biotech Showcase 2023
finance.yahoo.com - January 5 at 8:51 AM
finance.yahoo.com logoBiondVax CEO Issues Letter to Shareholders
finance.yahoo.com - December 30 at 9:24 AM
finance.yahoo.com logoAegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)
finance.yahoo.com - December 21 at 3:01 PM
msn.com logoWhy Biondvax Pharmaceuticals Stock Is Getting Obliterated During Friday's Trading Session
msn.com - December 16 at 6:15 PM
marketbeat.com logo
marketbeat.com - December 16 at 9:31 AM
finanznachrichten.de logoBiondVax Pharmaceuticals Ltd.: BiondVax Regains Nasdaq Compliance
finanznachrichten.de - December 13 at 11:57 AM
finance.yahoo.com logoIBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
finance.yahoo.com - December 13 at 11:57 AM
finance.yahoo.com logoBiondVax Regains Nasdaq Compliance
finance.yahoo.com - December 12 at 6:30 PM
finance.yahoo.com logoBVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb…
finance.yahoo.com - December 8 at 8:40 PM
finance.yahoo.com logoProfessor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
finance.yahoo.com - December 6 at 9:10 AM
finance.yahoo.com logoIBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
finance.yahoo.com - December 6 at 9:10 AM
finance.yahoo.com logoBiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - November 30 at 9:41 AM
Get BiondVax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.



BVXV Media Mentions By Week

BVXV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BVXV
News Sentiment
▼
0.00

0.50
▲
Average
Medical
News Sentiment

BVXV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BVXV Articles
This Week
▼
2

1
▲
BVXV Articles
Average Week

Get BiondVax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:BVXV) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -